Weiss Ratings Reiterates Hold (C-) Rating for Indivior (NASDAQ:INDV)

Key Points

• Weiss Ratings has reiterated a "hold (C-)" rating for Indivior (NASDAQ:INDV), amidst mixed opinions from other analysts regarding the stock.
• Indivior's recent earnings exceeded expectations, reporting $0.51 earnings per share and revenue of $302 million for the quarter.
• The stock recently traded at $24.07, with a market cap of $3.32 billion and an average price target of $22.00 according to consensus ratings.

Indivior (NASDAQ:INDV - Get Free Report)'s stock had its "hold (c-)" rating reiterated by equities research analysts at Weiss Ratings in a research note issued on Wednesday,Weiss Ratings reports.

A number of other equities analysts have also recently weighed in on the company. Craig Hallum increased their price target on Indivior from $27.00 to $34.00 and gave the stock a "buy" rating in a report on Wednesday, August 27th. Wall Street Zen upgraded Indivior from a "buy" rating to a "strong-buy" rating in a report on Saturday, June 21st. Jefferies Financial Group assumed coverage on Indivior in a research note on Tuesday, July 22nd. They set a "buy" rating and a $20.00 target price on the stock. Zacks Research lowered Indivior from a "strong-buy" rating to a "hold" rating in a research note on Friday, October 3rd. Finally, HC Wainwright assumed coverage on Indivior in a research note on Wednesday, August 6th. They set a "buy" rating and a $27.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and two have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $22.00.

Indivior Trading Up 1.5%

NASDAQ INDV opened at $24.07 on Wednesday. The stock has a market cap of $3.32 billion, a PE ratio of 38.82 and a beta of 0.70. Indivior has a twelve month low of $7.33 and a twelve month high of $25.10. The stock has a fifty day simple moving average of $23.37 and a 200-day simple moving average of $16.23.

Indivior (NASDAQ:INDV - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The company reported $0.51 earnings per share for the quarter, topping analysts' consensus estimates of $0.26 by $0.25. The business had revenue of $302.00 million during the quarter, compared to analysts' expectations of $239.43 million. Indivior had a negative return on equity of 86.28% and a net margin of 6.65%. Indivior has set its FY 2025 guidance at EPS. Research analysts predict that Indivior will post 1.22 EPS for the current year.

Institutional Investors Weigh In On Indivior

Several institutional investors have recently added to or reduced their stakes in the business. Nomura Holdings Inc. purchased a new stake in Indivior during the second quarter worth approximately $7,602,000. Tower Research Capital LLC TRC lifted its stake in Indivior by 851.1% in the second quarter. Tower Research Capital LLC TRC now owns 10,567 shares of the company's stock valued at $156,000 after buying an additional 9,456 shares during the last quarter. Krensavage Asset Management LLC lifted its stake in Indivior by 0.9% in the second quarter. Krensavage Asset Management LLC now owns 974,474 shares of the company's stock valued at $14,364,000 after buying an additional 9,106 shares during the last quarter. Rubric Capital Management LP lifted its stake in Indivior by 31.6% in the second quarter. Rubric Capital Management LP now owns 4,647,179 shares of the company's stock valued at $68,499,000 after buying an additional 1,117,140 shares during the last quarter. Finally, Gendell Jeffrey L lifted its stake in Indivior by 41.2% in the second quarter. Gendell Jeffrey L now owns 856,481 shares of the company's stock valued at $12,625,000 after buying an additional 250,000 shares during the last quarter. Hedge funds and other institutional investors own 60.33% of the company's stock.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.